ηγωεϊ εδεγςεϊ μςιϊεπεϊ
θας ξεγιςδ ςμ δϊεφΰεϊ δρετιεϊ ωμ ϊξεψϊ δξιζεβ αχωψ μψλιωϊ IVAX1/2/2006 θας ξεγιςδ ςμ δϊεφΰεϊ δρετιεϊ ωμ δαηιψεϊ ωπςωε ςμ ιγι αςμι ξπιεϊ IVAX αΰωψ μϊξεψϊ δξιζεβ ΰωψ ιχαμε αψλιωϊδ ωμ IVAX ςμ-ιγι θας , ΰωψ δεωμξδ α- 26 αιπεΰψ, 2006.
αδϊΰν μδρλν δψλιωδ ωπηϊν αιο δηαψεϊ, μαςμι ξπιεϊ IVAX διϊδ δζλεϊ μαηεψ αιο 0.8471 ξπιεϊ θας μαιο 26.00 γεμψ αξζεξο αϊξεψδ μλμ ξπιϊ IVAX ωααςμεϊν, αλτεσ μημεχδ ιηριϊ. αδϊαρρ ςμ ϊεφΰεϊ ρετιεϊ ωμ αηιψϊ αςμι δξπιεϊ, ϊξεψϊ δξιζεβ μϊωμεν μαςμι ξπιεϊ IVAX διπδ λγμχξο:
αηιψϊ ξπιεϊ: αςμι ξπιεϊ IVAX ΰωψ αιφςε αηιψδ ϊχτδ μχαμ ξπιεϊ αμαγ, ιχαμε 0.8471 ξπιεϊ θας μ- 51.90922% ξξπιεϊιδν α- IVAX ε- 26 γεμψ αξζεξο ςαεψ 48.09078% ξξπιεϊιδν α- IVAX, ΰε ΰτχθιαιϊ μλμ ξπιδ: 0.4397 ξπιεϊ θας ε- 12.50 γεμψ μλμ ξπιϊ IVAX ωμβαιδ πςωϊδ αηιψδ ζε;
αηιψϊ ξζεξο: αςμι ξπιεϊ IVAX ΰωψ αιφςε αηιψδ ϊχτδ μχαμ ξζεξο αμαγ, ιχαμε 26.00 γεμψ αξζεξο ςαεψ λμ ξπιδ ωμ IVAX ωμβαιδ πςωϊδ αηιψδ ζε.
μμΰ αηιψδ: αςμι ξπιεϊ IVAX ΰωψ μΰ αιφςε αηιψδ ϊχτδ ιχαμε 26.00 γεμψ αξζεξο ςαεψ λμ ξπιδ ωμ IVAX.
αδϊΰν μδρλν δξιζεβ, ημχι ξπιεϊ μΰ ιπϊπε εαξχεξο ιχαμε αςμι ξπιεϊ IVAX ξζεξο.
ξλϊα δεψΰεϊ μβαι δημτϊ δξπιεϊ εξλϊα δςαψδ ιωμηε αχψεα αγεΰψ μαςμι ξπιεϊ IVAX ΰωψ μΰ αηψε. αςμι ξπιεϊ IVAX ΰωψ αιφςε αηιψδ ϊχτδ αιο ξζεξο μξπιεϊ ΰιπν πγψωιν μπχεθ ατςεμδ περτϊ ςμ ξπϊ μχαμ ΰϊ ϊξεψϊ δξιζεβ.
ΰεγεϊ θας
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ διπδ ηαψδ βμεαμιϊ ωαριρδ αιωψΰμ εΰηϊ ξ- 20 δηαψεϊ δτψξφαθιεϊ δξεαιμεϊ αςεμν. θας, δξϊξηδ αιιφεψ ϊψετεϊ βπψιεϊ ειιηεγιεϊ εαιιφεψ ηεξψιν τςιμιν μϊςωιδ δτψξφαθιϊ ελξε λο ξεφψιν αϊηεν ψτεΰϊ αςμι-ηιιν, διπδ δηαψδ δξεαιμδ αςεμν αϊηεν δβπψιχδ. μθας ΰϊψι ιιφεψ, ξηχψ, ωιεεχ εδτφδ αιωψΰμ, αφτεο ΰξψιχδ εαΰιψετδ. χψεα μ- 90% ξξλιψεϊιδ ωμ δχαεφδ δο μφτεο ΰξψιχδ εΰιψετδ.
μδμο δρςισ διγες αΰψδ"α λ- Safe Harbor απερηε δΰπβμι εΰωψ ξθψϊε μδβο ςμ δηαψδ, ςτ"ι δγιο δΰξψιχΰι:
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
| © 1999 - 2008 λμ δζλειεϊ ωξεψεϊ μθας | ϊπΰι ωιξεω αΰϊψ | ξτϊ δΰϊψ |